Halaven
What Halaven is used for
Halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease (see section 5.1). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments. Halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5.1).
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Halaven
- Active substance
- eribulin
- Disease area
- Breast Neoplasms; Liposarcoma
- Medicine group
- Antineoplastic agents
- ATC code
- L01XX41
- Marketing authorisation holder
- Eisai GmbH
- Authorised in the EU since
- 2011
Official information
In the USA
Same active substance: Halaven
In India
- Eribulin: 8 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Halaven used for?
Halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease (see section 5.1). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments. Halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5.1).
What is the active substance in Halaven?
Halaven contains eribulin.
Who makes Halaven?
The EU marketing authorisation holder is Eisai GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU